Information Provided By:
Fly News Breaks for June 13, 2016
ALNY
Jun 13, 2016 | 08:20 EDT
Jefferies analyst Gena Wang lowered her price target for Alnylam Pharmaceuticals to $80 saying ALN-CC5 showed inadequate lactate dehydrogenase reduction in three Soliris-naive paroxysmal nocturnal hemoglobinuria patients and modest activity with 'CC5/Soliris combo. The analyst sees questions remaining in dosing, magnitude of drug effect, addressable patients population and pricing. Wang keeps a Buy rating on Alnylam.
News For ALNY From the Last 2 Days
There are no results for your query ALNY